What the study found
Denosumab combined with curettage after surgical dislocation of the hip successfully treated giant cell tumors of bone (GCTB) in the femoral head and neck.
Why the authors say this matters
The authors conclude that denosumab as adjuvant therapy had a favorable safety profile, with no drug-related complications observed, and that native hip joints were preserved with satisfactory functional outcomes.
What the researchers tested
This was a single-center retrospective study of denosumab treatment combined with curettage after surgical dislocation of the hip for GCTB in the femoral head and neck region.
What worked and what didn't
Native hip joints were preserved in all patients. The abstract reports no evidence of tumor recurrence or metastasis, and no drug-related complications were observed.
What to keep in mind
This summary provides only the information stated in the abstract. The abstract does not describe the number of patients, follow-up duration, or other limitations.
Key points
- Denosumab plus curettage after surgical dislocation of the hip successfully treated GCTB in the femoral head and neck.
- The authors report a favorable safety profile for denosumab as adjuvant therapy, with no drug-related complications.
- Native hip joints were preserved in all patients, with satisfactory functional outcomes.
- The abstract reports no evidence of tumor recurrence or metastasis.
Disclosure
- Research title:
- Denosumab and curettage preserved hips in femoral giant cell tumors
- Authors:
- Jimo Li, Dongfeng Cai, Zhuobin Yang, Jing Zhang, Qi Lv, Wenfeng Jin, Lvlin Zhao, Song Hong
- Institutions:
- Zunyi Medical University, Peking University, Beijing Jishuitan Hospital
- Publication date:
- 2026-01-08
- OpenAlex record:
- View
- Image credit:
- Photo by Funkcinės Terapijos Centras on Pexels · Pexels License
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.